Annual EBITDA
-$132.55 M
-$72.98 M-122.50%
December 31, 2023
Summary
- As of February 7, 2025, TARS annual EBITDA is -$132.55 million, with the most recent change of -$72.98 million (-122.50%) on December 31, 2023.
- During the last 3 years, TARS annual EBITDA has fallen by -$105.64 million (-392.70%).
- TARS annual EBITDA is now -9725.57% below its all-time high of -$1.35 million, reached on December 31, 2018.
Performance
TARS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$20.82 M
+$10.22 M+32.93%
September 30, 2024
Summary
- As of February 7, 2025, TARS quarterly EBITDA is -$20.82 million, with the most recent change of +$10.22 million (+32.93%) on September 30, 2024.
- Over the past year, TARS quarterly EBITDA has increased by +$19.78 million (+48.72%).
- TARS quarterly EBITDA is now -293.17% below its all-time high of $10.78 million, reached on March 31, 2021.
Performance
TARS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$126.97 M
+$17.26 M+11.97%
September 30, 2024
Summary
- As of February 7, 2025, TARS TTM EBITDA is -$126.97 million, with the most recent change of +$17.26 million (+11.97%) on September 30, 2024.
- Over the past year, TARS TTM EBITDA has increased by +$4.82 million (+3.66%).
- TARS TTM EBITDA is now -20248.08% below its all-time high of -$624.00 thousand, reached on September 30, 2019.
Performance
TARS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TARS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -122.5% | +48.7% | +3.7% |
| 3 y3 years | -392.7% | +48.7% | +3.7% |
| 5 y5 years | -9725.6% | +48.7% | +3.7% |
TARS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -884.8% | at low | -307.7% | +48.7% | -913.6% | +12.0% |
| 5 y | 5-year | -3010.7% | at low | -293.2% | +48.7% | -7417.6% | +12.0% |
| alltime | all time | -9725.6% | at low | -293.2% | +48.7% | <-9999.0% | +12.0% |
Tarsus Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$20.82 M(-32.9%) | -$126.97 M(-12.0%) |
| Jun 2024 | - | -$31.04 M(-10.1%) | -$144.23 M(+0.4%) |
| Mar 2024 | - | -$34.51 M(-15.0%) | -$143.64 M(+9.0%) |
| Dec 2023 | -$132.55 M(+122.5%) | -$40.60 M(+6.6%) | -$131.79 M(+26.7%) |
| Sep 2023 | - | -$38.08 M(+25.0%) | -$104.03 M(+18.5%) |
| Jun 2023 | - | -$30.45 M(+34.4%) | -$87.79 M(+40.6%) |
| Mar 2023 | - | -$22.66 M(+76.5%) | -$62.44 M(+4.7%) |
| Dec 2022 | -$59.57 M(+342.6%) | -$12.84 M(-41.2%) | -$59.66 M(-3.1%) |
| Sep 2022 | - | -$21.84 M(+327.6%) | -$61.58 M(+10.6%) |
| Jun 2022 | - | -$5.11 M(-74.3%) | -$55.70 M(+29.0%) |
| Mar 2022 | - | -$19.88 M(+34.7%) | -$43.19 M(+244.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$13.46 M(-50.0%) | -$14.76 M(-7.5%) | -$12.53 M(+36.1%) |
| Sep 2021 | - | -$15.96 M(-315.4%) | -$9.21 M(+173.3%) |
| Jun 2021 | - | $7.41 M(-31.3%) | -$3.37 M(-76.0%) |
| Mar 2021 | - | $10.78 M(-194.2%) | -$14.02 M(-47.9%) |
| Dec 2020 | -$26.90 M(+531.4%) | -$11.44 M(+13.0%) | -$26.90 M(+62.7%) |
| Sep 2020 | - | -$10.12 M(+211.7%) | -$16.53 M(+134.9%) |
| Jun 2020 | - | -$3.25 M(+54.4%) | -$7.04 M(+85.6%) |
| Mar 2020 | - | -$2.10 M(+97.5%) | -$3.79 M(+124.5%) |
| Dec 2019 | -$4.26 M(+215.9%) | -$1.06 M(+70.7%) | -$1.69 M(+170.7%) |
| Sep 2019 | - | -$624.00 K | -$624.00 K |
| Dec 2018 | -$1.35 M | - | - |
FAQ
- What is Tarsus Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals annual EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Tarsus Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Tarsus Pharmaceuticals?
- What is Tarsus Pharmaceuticals TTM EBITDA year-on-year change?
What is Tarsus Pharmaceuticals annual EBITDA?
The current annual EBITDA of TARS is -$132.55 M
What is the all time high annual EBITDA for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high annual EBITDA is -$1.35 M
What is Tarsus Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, TARS annual EBITDA has changed by -$72.98 M (-122.50%)
What is Tarsus Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of TARS is -$20.82 M
What is the all time high quarterly EBITDA for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high quarterly EBITDA is $10.78 M
What is Tarsus Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, TARS quarterly EBITDA has changed by +$19.78 M (+48.72%)
What is Tarsus Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of TARS is -$126.97 M
What is the all time high TTM EBITDA for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals all-time high TTM EBITDA is -$624.00 K
What is Tarsus Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, TARS TTM EBITDA has changed by +$4.82 M (+3.66%)